DAWN (Day One Biopharmaceuticals) Insider Ownership: 1.80 % (As of Jul. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DAWN Day One Biopharmaceuticals Inc DAWN
12 GF Score
Price $21.53
! 5 Warning Signs
View Full Analysis

What is Day One Biopharmaceuticals Insider Ownership?

Day One Biopharmaceuticals DAWN 12 Insider Ownership is 1.80 % as of Jul. 25, 2026. GuruFocus rates DAWN with a GF Score™ of 12/100. The stock has 5 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Day One Biopharmaceuticals's insider ownership is 1.80%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Day One Biopharmaceuticals's Institutional Ownership is 90.19%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Day One Biopharmaceuticals's Float Percentage Of Total Shares Outstanding is 85.01%.

Day One Biopharmaceuticals Insider Ownership Historical Data

* Premium members only.

The historical data trend for Day One Biopharmaceuticals's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Day One Biopharmaceuticals Insider Ownership Chart

Day One Biopharmaceuticals Historical Data

The historical data trend for Day One Biopharmaceuticals can be seen below:

2025-04-30 2025-05-31 2025-06-30 2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28
Insider Ownership 1.64 1.68 1.68 1.68 1.72 1.72 1.72 1.77 1.77 1.80
DAWN
12GF Score
Day One Biopharmaceuticals Inc DAWN
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Day One Biopharmaceuticals Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 1.80 % mean?
Day One Biopharmaceuticals (DAWN) has a Insider Ownership of 1.80 % as of Jul. 25, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Day One Biopharmaceuticals and its competitors.
Is Day One Biopharmaceuticals' Insider Ownership too high?
Day One Biopharmaceuticals' current Insider Ownership is 1.80 %. Overall, Day One Biopharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Day One Biopharmaceuticals' Insider Ownership compare to TYRA and DFTX?
Day One Biopharmaceuticals' Insider Ownership of 1.80 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Day One Biopharmaceuticals and its competitors. Day One Biopharmaceuticals's current Insider Ownership is 1.80 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Day One Biopharmaceuticals stock overvalued right now?
Day One Biopharmaceuticals (DAWN) has a current Insider Ownership of 1.80 %. The current Insider Ownership is 1.80 %. Day One Biopharmaceuticals' overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Day One Biopharmaceuticals (DAWN), the current Insider Ownership is 1.80 % as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Day One Biopharmaceuticals Business Description

Address 1800 Sierra Point Parkway, Suite 200, Brisbane, CA, USA, 94005
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.
12GF Score

Get the complete analysis for DAWN

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.53
Price